Dishman Carbogen AmicsNSE:DCAL -0.85%71 Current Ratio is 1.23 as of Mar. 2026, which is 1% below its 10-year median of 1.24. GuruFocus rates NSE:DCAL with a GF Score™ of 71/100 and a GF Value™ of ₹236.12 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Dishman Carbogen Amics ranks worse than 80.45% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Dishman Carbogen Amics's current ratio for the quarter that ended in Mar. 2026 was 1.23.
Dishman Carbogen Amics has a current ratio of 1.23. It generally indicates good short-term financial strength.
The historical rank and industry rank for Dishman Carbogen Amics's Current Ratio or its related term are showing as below:
NSE:DCAL'
s Current Ratio Range Over the Past 10 Years
Min: 0.75 Med: 1.24 Max: 1.32
Current: 1.23
During the past 13 years, Dishman Carbogen Amics's highest Current Ratio was 1.32. The lowest was 0.75. And the median was 1.24.
NSE:DCAL's Current Ratio is ranked worse than 80.45% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs NSE:DCAL: 1.23
Dishman Carbogen Amics (NSE:DCAL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Dishman Carbogen Amics Current Ratio Related Terms
Dishman Carbogen Amics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:DCAL vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Dishman Carbogen Amics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dishman Carbogen Amics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Dishman Carbogen Amics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dishman Carbogen Amics (NSE:DCAL) has a Current Ratio of 1.23 as of Mar. 2026. This is near median its historical median of 1.24. Over the past decade, Dishman Carbogen Amics' Current Ratio has ranged from 0.75 to 1.32. According to the industry distribution chart, Dishman Carbogen Amics ranks #1136 out of 1412 companies in the Biotechnology industry, placing it in the top 80.5%.
Is Dishman Carbogen Amics' Current Ratio too high?
Dishman Carbogen Amics' current Current Ratio of 1.23 is near median its 10-year median of 1.24. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 1.32. The Biotechnology industry median Current Ratio is 3.89. Dishman Carbogen Amics' value of 1.23 is 68.4% below this industry median. Based on the distribution chart, Dishman Carbogen Amics ranks #1136 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dishman Carbogen Amics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dishman Carbogen Amics ranks #1136 out of 1412 companies for Current Ratio. This places Dishman Carbogen Amics in the lower half of its industry. The industry median Current Ratio is 3.89. Dishman Carbogen Amics' value of 1.23 is 68.4% below this benchmark. Historically, Dishman Carbogen Amics' own Current Ratio has ranged from 0.75 to 1.32 over the past decade. While the company's 10-year median is 1.24 vs. the industry median of 3.89, Dishman Carbogen Amics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dishman Carbogen Amics's current Current Ratio of 1.23 is 68.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dishman Carbogen Amics's current Current Ratio is 1.23, which is near median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (NSE:DCAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹236.12, compared to a current price of ₹168.57 — trading 28.6% below its estimated fair value. The current Current Ratio is 1.23, which is near median its 10-year median of 1.24 and 68.4% below the Biotechnology industry median of 3.89. Dishman Carbogen Amics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Dishman Carbogen Amics (NSE:DCAL), the current Current Ratio is 1.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?
Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued.
The current stock price of ₹168.57 is trading 28.6% below its estimated GF Value™ of ₹236.12.
GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.
Key valuation signals for NSE:DCAL:
Current Ratio: 1.23 (near median its 10-year median of 1.24)
GF Value™: ₹236.12 vs. price of ₹168.57 (28.6% below fair value)
Industry Position: 68.4% below the Biotechnology median (#1136 of 1412)
No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
71GF Score
Get the complete analysis for NSE:DCAL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DCAL has been successfully added to your 
